{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:57:32Z","timestamp":1770278252429,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"China International Medical Exchange Foundation","award":["ChiCTR1900022364"],"award-info":[{"award-number":["ChiCTR1900022364"]}]},{"name":"China International Medical Exchange Foundation","award":["ChiCTR1900022364"],"award-info":[{"award-number":["ChiCTR1900022364"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-024-03644-7","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T01:58:47Z","timestamp":1735955927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study"],"prefix":"10.1186","volume":"23","author":[{"given":"Min","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanquan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feilong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guozheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"3","key":"3644_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"3644_CR2","first-page":"1116","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based Chemother plus Cetuximab head neck cancer. 2008;359(11):1116\u201327.","journal-title":"Platinum-based Chemother plus Cetuximab head neck cancer"},{"key":"3644_CR3","doi-asserted-by":"crossref","unstructured":"Gupta B, Johnson NW, Kumar NJO. Global epidemiology of head and neck cancers: a continuing challenge. 2016;91(1):13\u201323.","DOI":"10.1159\/000446117"},{"key":"3644_CR4","doi-asserted-by":"crossref","unstructured":"Viale PHJJotapio. The American Cancer Society\u2019s facts & figures: 2020 edition. 2020;11(2):135.","DOI":"10.6004\/jadpro.2020.11.2.1"},{"issue":"1","key":"3644_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11864-011-0176-y","volume":"13","author":"KA Price","year":"2012","unstructured":"Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 2012;13(1):35\u201346.","journal-title":"Curr Treat Options Oncol"},{"issue":"Suppl 7","key":"3644_CR6","doi-asserted-by":"publisher","first-page":"vii252","DOI":"10.1093\/annonc\/mdq453","volume":"21","author":"JB Vermorken","year":"2010","unstructured":"Vermorken JB, Specenier P. Optimal treatment for recurrent\/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252\u201361.","journal-title":"Ann Oncol"},{"issue":"1","key":"3644_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14737140.2020.1708197","volume":"20","author":"A Rajendra","year":"2020","unstructured":"Rajendra A, Noronha V, Joshi A, Patil VM, Menon N, Prabhash K. Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects. Expert Rev Anticancer Ther. 2020;20(1):17\u201329.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"3644_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725\u201341.","journal-title":"Nat Rev Clin Oncol"},{"key":"3644_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune Checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"3644_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, Soulieres D, Tahara M, de Castro G Jr., et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic Head and Neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023;41(4):790\u2013802.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3644_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM197708112970617","volume":"297","author":"T Bernstein","year":"1977","unstructured":"Bernstein T. Skin reactions to 5-fluorouracil. N Engl J Med. 1977;297(6):337\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"3644_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3816\/CCC.2005.n.020","volume":"5","author":"MW Saif","year":"2005","unstructured":"Saif MW. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer. 2005;5(2):89\u2013100.","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"3644_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5694\/mja2.50317","volume":"211","author":"SK Das","year":"2019","unstructured":"Das SK, Das AK, William M. 5-Fluorouracil-induced acute coronary syndrome. Med J Aust. 2019;211(6):255\u2013e71.","journal-title":"Med J Aust"},{"issue":"6","key":"3644_CR14","doi-asserted-by":"publisher","first-page":"100746","DOI":"10.1016\/j.currproblcancer.2021.100746","volume":"45","author":"M Ozer","year":"2021","unstructured":"Ozer M, Dumas B, Horta L, Sadrzadeh H. 5-Fluorouracil associated neurovascular toxicities. Curr Probl Cancer. 2021;45(6):100746.","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"3644_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10120-011-0043-3","volume":"14","author":"T Hara","year":"2011","unstructured":"Hara T, Nishikawa K, Sakatoku M, Oba K, Sakamoto J, Omura K. Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer. Gastric Cancer. 2011;14(4):332\u20138.","journal-title":"Gastric Cancer"},{"issue":"12","key":"3644_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021;17(12):1455\u201366.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"3644_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.yexcr.2017.12.018","volume":"362","author":"CR Millrud","year":"2018","unstructured":"Millrud CR, Mehmeti M, Leandersson K. Docetaxel promotes the generation of anti-tumorigenic human macrophages. Exp Cell Res. 2018;362(2):525\u201331.","journal-title":"Exp Cell Res"},{"issue":"20","key":"3644_CR18","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-17-3480","volume":"78","author":"CW Wanderley","year":"2018","unstructured":"Wanderley CW, Colon DF, Luiz JPM, Oliveira FF, Viacava PR, Leite CA, et al. Paclitaxel reduces Tumor Growth by Reprogramming Tumor-Associated macrophages to an M1 Profile in a TLR4-Dependent manner. Cancer Res. 2018;78(20):5891\u2013900.","journal-title":"Cancer Res"},{"issue":"24","key":"3644_CR19","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-14-1913","volume":"74","author":"F Parikh","year":"2014","unstructured":"Parikh F, Duluc D, Imai N, Clark A, Misiukiewicz K, Bonomi M, et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res. 2014;74(24):7205\u201316.","journal-title":"Cancer Res"},{"issue":"11","key":"3644_CR20","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","volume":"14","author":"CT Garnett","year":"2008","unstructured":"Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536\u201344.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3644_CR21","doi-asserted-by":"publisher","first-page":"e1008866","DOI":"10.1080\/2162402X.2015.1008866","volume":"4","author":"J Pol","year":"2015","unstructured":"Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. Trial Watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4(4):e1008866.","journal-title":"Oncoimmunology"},{"key":"3644_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","volume":"121","author":"K Saleh","year":"2019","unstructured":"Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2019;121:123\u20139.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3644_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12672-023-00774-4","volume":"14","author":"A Sakai","year":"2023","unstructured":"Sakai A, Ebisumoto K, Iijima H, Yamauchi M, Teramura T, Yamazaki A, et al. Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors. Discov Oncol. 2023;14(1):158.","journal-title":"Discov Oncol"},{"key":"3644_CR24","doi-asserted-by":"crossref","unstructured":"Gui L, He X, Yang J, Liu P, Yan Q, Shi YJAO. 683P pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phase II study. 2022;33:S855\u20136.","DOI":"10.1016\/j.annonc.2022.07.807"},{"key":"3644_CR25","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer (Oxford, England: 1990). 2009;45(2):228\u2009\u2013\u200947.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"3644_CR26","doi-asserted-by":"crossref","unstructured":"Dzienis M, Cundom J, Fuentes C, Hansen A, Nordlinger M, Pastor A et al. 651O Pembrolizumab (pembro)\u2009+\u2009carboplatin (carbo)\u2009+\u2009paclitaxel (pacli) as first-line (1L) therapy in recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC): phase VI KEYNOTE-B10 study. 2022;33:S839\u201340.","DOI":"10.1016\/j.annonc.2022.07.775"},{"key":"3644_CR27","doi-asserted-by":"publisher","first-page":"1348045","DOI":"10.3389\/fonc.2024.1348045","volume":"14","author":"CM Black","year":"2024","unstructured":"Black CM, Zheng D, Hair GM, Ai L, Wang L, Goto D, et al. Real-world use of first-line pembrolizumab\u2009+\u2009platinum\u2009+\u2009taxane combination regimens in recurrent \/ metastatic head and neck squamous cell carcinoma. Front Oncol. 2024;14:1348045.","journal-title":"Front Oncol"},{"key":"3644_CR28","doi-asserted-by":"publisher","first-page":"105634","DOI":"10.1016\/j.oraloncology.2021.105634","volume":"124","author":"T Fuereder","year":"2022","unstructured":"Fuereder T, Minichsdorfer C, Mittlboeck M, Wagner C, Heller G, Putz EM, et al. Pembrolizumab plus Docetaxel for the treatment of recurrent\/metastatic head and neck cancer: a prospective phase I\/II study. Oral Oncol. 2022;124:105634.","journal-title":"Oral Oncol"},{"issue":"6","key":"3644_CR29","doi-asserted-by":"publisher","first-page":"103476","DOI":"10.1016\/j.esmoop.2024.103476","volume":"9","author":"T Koyama","year":"2024","unstructured":"Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, et al. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody. ESMO Open. 2024;9(6):103476.","journal-title":"ESMO Open"},{"issue":"11","key":"3644_CR30","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1002\/lary.27807","volume":"129","author":"E Du","year":"2019","unstructured":"Du E, Mazul AL, Farquhar D, Brennan P, Anantharaman D, Abedi-Ardekani B, et al. Long-term survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and human papillomavirus status. Laryngoscope. 2019;129(11):2506\u201313.","journal-title":"Laryngoscope"},{"issue":"4","key":"3644_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.scib.2023.12.046","volume":"69","author":"SY Maggie Liu","year":"2024","unstructured":"Maggie Liu SY, Huang J, Deng JY, Xu CR, Yan HH, Yang MY, et al. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): a phase 2, randomized, controlled trial. Sci Bull (Beijing). 2024;69(4):535\u201343.","journal-title":"Sci Bull (Beijing)"},{"issue":"3","key":"3644_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12032-018-1087-6","volume":"35","author":"H Fuchs","year":"2018","unstructured":"Fuchs H, Pammer J, Minichsdorfer C, Posch D, Kornek G, Aretin MB, et al. Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent\/metastatic head and neck cancer. Med Oncol. 2018;35(3):32.","journal-title":"Med Oncol"},{"issue":"2","key":"3644_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5306\/wjco.v13.i2.147","volume":"13","author":"A Falco","year":"2022","unstructured":"Falco A, Leiva M, Blanco A, Cefarelli G, Rodriguez A, Melo J, et al. First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: a multicenter cohort study. World J Clin Oncol. 2022;13(2):147\u201358.","journal-title":"World J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03644-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03644-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03644-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T14:01:43Z","timestamp":1735999303000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03644-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3644"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03644-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of The Second Xiangya Hospital (Approval number: 2023 Lun Audit No. K062).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}